Difference between revisions of "Tafasitamab (Monjuvi)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity ==Preliminary data== ===[[Chronic lymphocytic leukemia (CLL)...") |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]]=== | ===[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]]=== | ||
| − | # Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. Epub 2014 Oct 9. [ | + | # Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. Epub 2014 Oct 9. [https://www.ncbi.nlm.nih.gov/pubmed/25301708 PubMed] |
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 02:44, 2 December 2016
Mechanism of action
Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity
Preliminary data
Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. Epub 2014 Oct 9. PubMed